New drug BIVV020 shows promise for chronic ITP in small trial

NCT ID NCT04669600

Completed Disease control Sponsor: Bioverativ, a Sanofi company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2a trial tested the drug BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The main goal was to see if BIVV020 could help maintain a safe platelet count over time and reduce the need for emergency treatments. The study was small and open-label, meaning everyone knew they were getting the drug, so results are preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BIVV020 (SAR445088)
What this could lead to: If successful, BIVV020 could offer a new treatment option for people with chronic immune thrombocytopenia (ITP) to help maintain safe platelet levels.
What could go wrong: This was a very small, early-phase trial with only 12 participants, so results may not apply to everyone. The drug may cause side effects or not work as well in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

Investigational Site Number :2030002

Ostrava - Poruba, 70852, Czechia
Investigational Site Number :2760001

Essen, 45147, Germany
Investigational Site Number :5280001

Leiden, 2333 ZA, Netherlands
Investigational Site Number :7240001

Palma de Mallorca, 07120, Spain
Investigational Site Number :7240002

A Coruña, A Coruña [La Coruña], 15006, Spain
Investigational Site Number :7240003

Seville, 41013, Spain
Investigational Site Number :8260002

London, London, City of, W12 0HS, United Kingdom
Investigational Site Number :8400001

Washington D.C., District of Columbia, 20007, United States
Investigational Site Number :8400002

Tamarac, Florida, 33321, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.